3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
4
Unknown
2
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Small Cell Lung Carcinoma
27
Lymphoma, Large B-Cell, Diffuse
10
Lung Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Non-Hodgkin
6
Lymphoma, B-Cell
6
Hodgkin Disease
6
Burkitt Lymphoma
6
Neuroblastoma
5
Medulloblastoma
5
Neoplasms, Germ Cell and Embryonal
4
Leukemia, Myeloid, Acute
4
Small Cell Lung Cancer Extensive Stage
3
Seminoma
3
Retinoblastoma
3
Recurrence
3
Ovarian Neoplasms
3
Multiple Myeloma
3
Lymphoma
3
Carcinoma, Neuroendocrine
3
Brain Neoplasms
3
Wilms Tumor
2
Urinary Bladder Neoplasms
2
Teratoma
2
Sarcoma, Ewing
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Neuroectodermal Tumors, Primitive
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Interventions
pembrolizumab
6
cabozantinib
6
Nivolumab
5
Ipilimumab
5
Axitinib
5
Radiosurgery
3
Blood Specimen Collection
3
zimberelimab
2
lenvatinib
2
Ultrasonography
2
Radiotherapy
2
Biopsy
2
tislelizumab
1
polyethylene glycol 3350
1
pazopanib
1
palbociclib
1
orellanine
1
olaparib
1
gallium Ga 68 dotatate
1
fludarabine
1
cyclopropapyrroloindole
1
brodalumab
1
belzutifan
1
atezolizumab
1
anlotinib
1
adagrasib
1
Watchful Waiting
1
Vincristine
1
Therapeutics
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Kidney Neoplasms
×
Etoposide
×
Clear all
NCT05384821
2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2
Recruiting
28 enrolled